Breaking News: The FDA approved Eli Lilly’s drug, tirzepatide, for the treatment of obesity! The name for this drug is  Zepbound™ and it is, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound, like all other AOMs,  is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight/ preobesity  (with a BMI of 27 kg/m2 or greater) and also have weight-related complications.In this episode, Karli reviews the news release and discusses things like, when Zepbound is expected to be available, pricing, and the studies that lead to its FDA appoval. News ReleaseSurmount 3Support the showThe Gaining Health Podcast will release a new episode every Wednesday, alternating between interviews with experts and "What's Up Wednesday" scientific updates.For a roadmap for developing an obesity program, editable forms and templates, patient education materials, and more, check out Gaining Health If you are loving this podcast, please consider supporting us on Patreon